Codexis appointed Dr. Arthur Levin to its Strategic Advisory Board, enhancing its expertise in oligonucleotide therapeutics development.
Quiver AI Summary
Codexis, Inc. announced the addition of Dr. Arthur Levin to its Strategic Advisory Board, bringing over 30 years of experience in oligonucleotide development. Dr. Levin, a founding member of Avidity Biosciences and a recognized leader in RNA therapeutics, will provide strategic guidance as Codexis advances its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis manufacturing platform. His expertise includes the development of key therapeutic oligonucleotides, including the first approved antisense drugs. Codexis aims to enhance the manufacturing of RNAi therapeutics through its proprietary enzymatic technology, addressing challenges in pharmaceutical production while improving efficiency and sustainability.
Potential Positives
- Appointment of Dr. Arthur Levin to the Strategic Advisory Board brings a wealth of experience in oligonucleotide development, enhancing Codexis' expertise in RNA therapeutics.
- Dr. Levin's background includes contributions to the first approved antisense drugs and the first microRNA-targeted therapeutic, positioning Codexis favorably in the RNA therapeutics landscape.
- The Strategic Advisory Board, which now includes distinguished leaders in biotechnology, plays a pivotal role in guiding Codexis’ strategic direction and development of the ECO Synthesis™ platform.
- Codexis is actively expanding its capabilities in RNAi therapeutics, which could lead to significant market opportunities and growth prospects as the sector experiences increased momentum.
Potential Negatives
- The appointment of Dr. Levin may raise concerns about Codexis' reliance on external advisors to drive strategic direction, potentially signaling a lack of sufficient internal expertise in critical areas such as RNA therapeutics.
- The press release highlights heavy dependence on the future success of the ECO Synthesis™ platform, which may increase pressure for Codexis to deliver results in a competitive landscape.
- Risks associated with forward-looking statements, including reliance on collaborators and potential need for additional capital, indicate uncertainty in Codexis' business strategy and operational stability.
FAQ
Who is Arthur Levin, PhD?
Arthur Levin is a distinguished expert in oligonucleotide development and a founding member of Avidity Biosciences, with three decades of experience in the field.
What is Codexis' ECO Synthesis manufacturing platform?
Codexis' ECO Synthesis™ platform enables efficient and scalable manufacturing of RNAi therapeutics using enzymatic technologies.
What role does the Strategic Advisory Board play at Codexis?
The Strategic Advisory Board provides expert guidance and insights to support Codexis' strategic direction and the development of its technologies.
How many members are on the Codexis Strategic Advisory Board?
The Codexis Strategic Advisory Board comprises several experts, including notable leaders like John Maraganore and Masad Damha.
What are Codexis' main products and services?
Codexis specializes in enzymatic solutions for therapeutics manufacturing and develops high-performance enzymes for small molecule pharmaceuticals and nucleic acid synthesis.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CDXS Insider Trading Activity
$CDXS insiders have traded $CDXS stock on the open market 12 times in the past 6 months. Of those trades, 12 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CDXS stock by insiders over the last 6 months:
- MANAGEMENT INC. OPALEYE has made 12 purchases buying 1,381,000 shares for an estimated $4,316,854 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CDXS Hedge Fund Activity
We have seen 62 institutional investors add shares of $CDXS stock to their portfolio, and 44 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CASDIN CAPITAL, LLC added 6,100,000 shares (+305.0%) to their portfolio in Q3 2024, for an estimated $18,788,000
- OPALEYE MANAGEMENT INC. added 5,315,000 shares (+153.8%) to their portfolio in Q3 2024, for an estimated $16,370,200
- MILLENNIUM MANAGEMENT LLC added 1,328,134 shares (+1846.6%) to their portfolio in Q3 2024, for an estimated $4,090,652
- ASSENAGON ASSET MANAGEMENT S.A. removed 815,578 shares (-73.9%) from their portfolio in Q4 2024, for an estimated $3,890,307
- PARADIGM CAPITAL MANAGEMENT INC/NY removed 800,000 shares (-88.9%) from their portfolio in Q3 2024, for an estimated $2,464,000
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 661,814 shares (-18.2%) from their portfolio in Q3 2024, for an estimated $2,038,387
- AMERIPRISE FINANCIAL INC added 384,280 shares (+19.2%) to their portfolio in Q3 2024, for an estimated $1,183,582
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Arthur Levin, PhD, to the Company’s Strategic Advisory Board (SAB). Dr. Levin is a founding member of Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called antibody oligonucleotide conjugates, and currently serves on its Board of Directors. He brings three decades of experience developing oligonucleotides to Codexis as it continues to onboard customers for its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufacturing platform.
“We are thrilled to have such a distinguished oligonucleotide leader as Art Levin join our SAB,” said Stefan Lutz, PhD, Senior Vice President of Research at Codexis. “With extensive experience in the development of numerous oligonucleotides, including the first approved antisense drugs and the first microRNA-targeted therapeutic in clinical trials, Art will provide invaluable guidance as we continue on our growth trajectory with the ECO Synthesis platform.”
Dr. Levin added, “I am excited to partner with Codexis as it expands the possibility of RNAi therapeutics through its groundbreaking enzymatic technologies. As someone who has been in the oligonucleotide business for decades, it is exciting to see momentum for the space increasing so drastically. I look forward to working with the management team and SAB to help usher Codexis through this next phase of growth.”
In addition to his role on the Board of Directors, Dr. Levin previously held the positions of Distinguished Scientist, Strategic Leader and Chief Scientific Officer at Avidity. Dr. Levin is a highly regarded key opinion leader in the RNA therapeutics field who has led teams responsible for the development of many oligonucleotides. Prior to joining Avidity, Dr. Levin was the Executive Vice President of Research and Development at miRagen Therapeutics and held senior drug development roles at Ionis (formerly Isis) Pharmaceuticals and Santaris Pharmaceuticals. He has published more than 100 scientific articles and has authored several of the most cited reviews in the field. In addition to Codexis, he serves on the scientific advisory boards of multiple institutions. Dr. Levin received a doctorate in toxicology from the University of Rochester and holds a bachelor’s degree in biology from Muhlenberg College.
About the Codexis Strategic Advisory Board
Codexis’ Strategic Advisory Board (SAB) was established in 2023 and is comprised of experts across oligonucleotide synthesis, manufacturing and commercialization. The SAB plays a pivotal role in guiding the Company’s strategic direction and offers valuable insights to inform the continued development of the ECO Synthesis™ manufacturing platform. Current members include John Maraganore, PhD, founder and former Chief Executive Officer of Alnylam Pharmaceuticals; Masad Damha, PhD, Distinguished James McGill Professor at McGill University; Jim Lalonde, PhD, biotechnology consultant for start-up companies in enzyme engineering and former Senior Vice President of Research and Development at Codexis; and Carole Cobb, MBA, biotechnology consultant and former Chief Operating Officer at GreenLight Biosciences. More information about Codexis’ SAB can be found on the About Us section of the Company’s corporate website,
located here
.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver
®
technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit
https://www.codexis.com
.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “suggest,” “target,” “on track,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management, including but not limited to statements regarding the potential of the ECO Synthesis™ platform, and it providing an opportunity for Codexis to efficiently capture meaningful market share. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis’ dependence on its licensees and collaborators; if any of its collaborators terminate their development programs under their respective license agreements with Codexis; Codexis may need additional capital in the future in order to expand its business; if Codexis is unable to successfully develop and commercialize new technology such as its ECO Synthesis™ platform and its dsRNA ligase; Codexis dependence on a limited number of products and customers, and potential adverse effects to Codexis’ business if its customers’ products are not received well in the markets; if competitors and potential competitors who have greater resources and experience than Codexis develop products and technologies that make Codexis’ products and technologies obsolete; if Codexis is unable to accurately forecast financial and operational performance; and market and economic conditions may negatively impact Codexis business, financial condition and share price. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 28, 2024 and in Codexis’ Quarterly Report on Form 10-Q filed with the SEC on October 31, 2024, including under the caption “Risk Factors,” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com
A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/e3137aaa-14c6-4e44-b71a-cb4b8bc4e4cb
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
